Eurosurveillance banner
HOME
ARCHIVES
ABOUT US
Editorial policy
For Authors
For Reviewers
Links
15-Year Anniversary
Search
Submit article Submit article
Eurosurveillance RSS RSS Feed
Eurosurveillance subscribe Subscribe
Eurosurveillance unsubscribe Unsubscribe
Contact Eurosurveillance Contact
Sitemap Sitemap

Announcements
Twitter
Follow Eurosurveillance on Twitter: @Eurosurveillanc
View all announcements All announcements
In this issue
Fatal and mild primary dengue virus infections imported to Norway from Africa and south-east Asia, 2008-2010
Public health advice based on routine mumps surveillance in England and Wales
Risk factors for disease severity among hospitalised patients with 2009 pandemic influenza A (H1N1) in Spain, April – December 2009
European Medicines Agency updates on the review of Pandemrix and reports of narcolepsy
In the national epidemiological bulletins - a selection from current issues


Home Eurosurveillance Edition  2010: Volume 15/ Issue 38 Article 4 Printer friendly version
Back to Table of Contents
Previous Download (pdf) Next
Eurosurveillance, Volume 15, Issue 38, 23 September 2010
News
European Medicines Agency updates on the review of Pandemrix and reports of narcolepsy
Eurosurveillance editorial team ()1
  1. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
Citation style for this article: Eurosurveillance editorial team. European Medicines Agency updates on the review of Pandemrix and reports of narcolepsy. Euro Surveill. 2010;15(38):pii=19670. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19670
Date of submission: 23 September 2010
The European Medicines Agency’s Committee for Medicinal Products for Human Use today 23 September 2010 announced that it has reviewed all available data on the suspected link between narcolepsy and Pandemrix and concludes that the available evidence is insufficient to determine whether there is any link between the illness and the vaccine.

The Committee agrees that further studies are necessary to understand the issue fully and that while the review is still ongoing there is no need for Europe-wide restrictions on the use of Pandemrix. The ongoing review will take some three to six months to conclude and will require new epidemiological research to establish conclusions on the possibility of a link between Pandemrix and narcolepsy.

Until mid-September there were 81 reports from healthcare professionals which suggested narcolepsy. Of these the majority came from Sweden (34) and Finland (30), 10 from France, six from Norway and one from Portugal.

To read more about the issue, please visit the website of the European Medicines Agency: www.ema.europa.eu

Back to Table of Contents
Previous Download (pdf) Next
Disclaimer:The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal.
The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement.

Eurosurveillance [ISSN] - ©2007-2013. All rights reserved
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.